UNSPSC 51361932: Butabarbital sodium

This classification denotes a barbiturate with the molecular formula C10H15N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9WTD50I918, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylpropyl)- but more generally known as butabarbital sodium, which bears US NIH Compound Identifier 2479. European Medicines Agency schedules Secbutabarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04343MIG.

Most nations, for tariff and trade purposes, schedule butabarbital sodium under HS 29335300. As of Q4 2014, BUTABARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Butabarbital sodium bears US NLM identifiers UMLS ID C0304358 and NCI Concept Code C65275. SMILES: CCC(C)C1(C(=O)NC(=O)[N-]C1=O)CC.[NA+].

UNSPSC 51361932 Butabarbital sodium is a Commodity code whose nominal scope—a barbiturate medication—shows little alignment with recent state and local procurement activity tagged under it. The three most recent opportunities posted under this code solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription fulfillment capabilities, and generic multi-source pharmaceuticals and OTC products. None of these solicitations mention butabarbital sodium or barbiturate drugs specifically. State and local governments posting under this code are acquiring pharmaceutical products and services through health departments, state HHS commissions, and cooperative purchasing alliances, but the actual goods and services being procured diverge substantially from the code's nominal pharmaceutical line item.

The three recent opportunities span Florida, Texas, and Minnesota through a multistate cooperative. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with responses due July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. This code shows active procurement but the mismatch between the nominal UNSPSC commodity and the actual work being bought suggests either tagging inconsistency or that the code's scope no longer reflects current state and local pharmaceutical purchasing.